HELP RESTORE REALITY WITH NUPLAZID 34 mg2,3
The only FDA-approved therapy proven to reduce delusions and hallucinations associated with PD psychosis in elderly patients*†
*In the pivotal trial, 88% of patients on NUPLAZID 34 mg were aged 65-85 years.4
†NUPLAZID reduces the frequency and/or severity of delusions and hallucinations associated with PD psychosis.
One small* 34 mg capsule formulation2
Parkinson’s disease-related delusions and hallucinations are common and distort what is real1,5
NUPLAZID 34 mg has a demonstrated safety profile in elderly patients with PD psychosis2
In the 6-week studies, 80% of patients in NUPLAZID clinical studies were aged 65 years or older*
No differences in safety were reported based on age, gender, or MMSE score
27% of patients had mild cognitive impairment (MMSE 21-24)
The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%)
*The maximum age in the clinical studies was 90 years.6
MMSE=Mini-Mental State Examination.
The only FDA-approved therapy proven to reduce delusions and hallucinations associated with PD psychosis in elderly patients… without impacting motor function2,3*
*As measured by United Parkinson’s Disease Rating Scale Parts II and III (UPDRS II+III).
NUPLAZID showed continuous improvement over 6 weeks
Results from a Phase 3, randomized, multicenter, double-blind, placebo-controlled, parallel-group study of PD psychosis patients (N=199).2,3 Primary endpoint was change from baseline at 6 weeks in the 9-item SAPS-PD. Doses of PD medications taken prior to baseline were required to be stable 30 days prior to study start and throughout the study period. Mean baseline score was 15.9 for NUPLAZID and 14.7 for placebo. The mean age of patients enrolled in the clinical study with NUPLAZID was 72 years.3 While the primary endpoint was designed to measure change from baseline to Week 6, a statistically significant difference between NUPLAZID and placebo was observed at Week 4 (P=0.0369) and again at Week 6 (P=0.0014).
LSM=least-squares mean; SAPS-PD=Scale for Assessment of Positive Symptoms-Parkinson’s Disease; SE=standard error.
ONE FDA-approved treatment, ONE small* capsule, ONE daily dose2
*Actual size is 14.3 mm X 5.3 mm.
Proposed mechanism of action for NUPLAZID2*
*The precise mechanism of action of NUPLAZID in the treatment of delusions and hallucinations associated with Parkinson’s disease psychosis is unclear. However, the effect of NUPLAZID could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.
NUPLAZIDconnectTM makes it easy to start your patients on NUPLAZID and provides the support they deserve.
Get your patients started on NUPLAZID right away with a free 14-day supply.*
*Appropriate patients must be enrolled in NUPLAZIDconnect to be eligible for the free 14-day supply of NUPLAZID.